Expansion of High Content Screening Capabilities at the National Center for Drug Screening in China
The National Center for drug screening (NCDS) located in Shanghai, China and Cellomics, Inc. announced an addition to their strategic collaboration aimed at expanding the application of High Content Screening (HCS) technologies in China. Affiliated with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, the Center is a key national technology innovation base in drug discovery and development.
The expansion of this collaboration is facilitated by two key events. First, the NCDS has completed their HCS portfolio of research and discovery tools through the acquisition of the KineticScan(R) HCS Reader, Cellomics' premier instrument for performing live-cell, kinetic HCS assays. The second part of this expansion includes the organization and sponsorship of a nationwide HCS Workshop to be held at the NCDS in Shanghai, between April 4 and 6, 2005.
"The adoption of Cellomics' live-cell imaging system, the KineticScan HCS Reader is vital to expanding our research programs in cell-based high content screening," stated Dr. Ming-Wei Wang, Director of the NCDS. "By adding the capabilities of the KineticScan to those we already have with Cellomics' ArrayScan(R) HCS Reader, we are able to quickly execute our strategic plan of utilizing HCS technologies in our drug discovery and development efforts," continued Dr. Wang.
Most read news
Organizations
Other news from the department science
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic World Cell Analysis
Cell analyse advanced method allows us to explore and understand cells in their many facets. From single cell analysis to flow cytometry and imaging technology, cell analysis provides us with valuable insights into the structure, function and interaction of cells. Whether in medicine, biological research or pharmacology, cell analysis is revolutionizing our understanding of disease, development and treatment options.
Topic World Cell Analysis
Cell analyse advanced method allows us to explore and understand cells in their many facets. From single cell analysis to flow cytometry and imaging technology, cell analysis provides us with valuable insights into the structure, function and interaction of cells. Whether in medicine, biological research or pharmacology, cell analysis is revolutionizing our understanding of disease, development and treatment options.
Last viewed contents
Breakthrough: Previously unknown compound in chloraminated drinking water identified - Identifying the compound required a more complete understanding of chemistry and better analytical instrumentation
Promising discovery for a non-invasive early detection of Alzheimer's disease
CyBio Well vario | Pipetting systems | Analytik Jena
Researchers successfully test device that analyzes components within a vacuum
Study finds potential new biomarker for cancer patient prognosis
The "profile" of neon becomes more exact - PTB researchers determine the polarizability of neon with extreme accuracy - their procedure helps to revise theoretical models and is also of use for other elements
Domestic cat genome sequenced
SPECTRO Reaches Milestone with Shipment of 40,000th Instrument
Cells bulge to squeeze through barriers
Johnson & Johnson Nordic AB Acquires Amic - Gains Access to In Vitro Diagnostic Technologies in Development for Use in Point-of-Care Settings
ATLAS Biolabs fulfills the DIN EN ISO 13485:2003 + AC: 2009 standard for designing and manufacturing medical devices